Rikki Rockett, the drummer for the rock band Poison, is celebrating ten years of survival after battling stage 4 throat cancer. He credits an experimental drug trial at UC San Diego for saving his tongue and his life.
How a UC San Diego drug combination saved Rikki Rockett's tongue
After standard chemotherapy and radiation failed to stop the progression of his disease, Rikki Rockett turned to the UC San Diego Moores Cancer Center. As reported by Fox News Digital, Rockett participated in a clinical trial that utilized a combination of pembrolizumab (marketed as Keytruda) and epacadostat. This experimental approach proved remarkably effective for the musician.
The results were rapid and dramatic. According to the report, Rockett's first PET scan revealed that 90 percent of the cancer had vanished, and a second scan showed the cancer was entirely gone. By July 2016, the drummer was officially declared free of throat cancer, avoiding a surgery that would have removed his tongue.
A drop to 161 pounds and recorded messages for his children
The physical and emotional toll of the illness was severe. Rikki Rockett wrote in his new memoir, Ghost Notes: My Life in Poison, that he eventually became unable to consume solid food, relying solely on water, shakes, and soup. This dietary restriction caused his weight to plummet to 161 pounds.
Facing the possibility that doctors would have to surgically remove his tongue, Rockett began recording voice messages for his children. He wanted his children to have a permanent record of his voice and his life advice, fearing that he would not survive the ordeal or would be left unablle to communicate. This period of desperation highlighted the high stakes of the experimental trial he eventually entered.
The Philadelphia chromosome and the battle with chronic myeloid leukemia
Recovery from throat cancer was interrupted by a second , unrelated diagnosis. Eight months into his recovery, Rikki Rockett discovered he had chronic myeloid leukemia (CML), a blood cancer linked to a genetic abnormality known as the Philadelphia chromosome. This translocation between chromosomes creates a predisposition to the disease .
Under the care of a hematologist named Dr. Jaimeson, Rockett began a medication regimen that has kept the CML in 100 percent remission for several years. While the medication carries "nasty side effects," it has allowed the Poison drummer to maintain his health and continue his career.
The rising tide of HPV-related throat cancers
Rikki Rockett's diagnosis of HPV-related throat cancer is part of a broader, concerning trend in oncology. Human Papillomavirus (HPV) is increasingly recognized as a primary driver of oropharyngeal cancers, which affect the back of the throat, tonsils, and base of the tongue. Unlike traditional throat cancers linked to smoking and alcohol, HPV-related cases are appearing more frequently in younger populations and non-smokers.
This shift in epidemiology has pushed medical institutions to explore more aggressive immunotherapy options, such as the pembrolizumab treatment Rockett received. The success of these trials often provides the blueprint for new standard-of-care protocols for thousands of other patients facing similar stage 4 diagnoses.
The current status of the pembrolizumab and epacadostat combination
While the combination of pembrolizumab and epacadostat worked for Rikki Rockett, the broader clinical efficacy of epacadostat has been a subject of significant medical debate. the source does not specify if this specific drug pairing has since become a standard treatment or if it remains restricted to trial settings.
Additionally, it remains unclear what specific "nasty side effects" Rockett continues to endure from his CML medication. Because the report focuses on the milestone of survival, the long-term maintenance requirements for his leukemia remission are not fully detailed.
Comments 0